NOR-TEST is a multi-centre PROBE ( prospective randomised , open-label , blinded endpoint ) trial designed to establish superiority of tenecteplase @ mg/kg ( single bolus ) as compared with alteplase @ mg/kg ( @ % bolus +@ % infusion/@minutes ) for consecutively admitted patients with acute ischaemic stroke eligible for thrombolytic therapy , i.e. patients a ) admitted < @hours after symptoms onset ; b ) admitted < @hours after awakening with stroke symptoms c ) receiving bridging therapy before embolectomy.Randomisation tenecteplase : alteplase is @:@ .